Danyang Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Danyang Li has a total of 215 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Mark McIntosh
Royal Infirmary Edinburgh
7 shared publications - Cathryn M. Lewis
Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
7 shared publications Gerome Breen
King’s College London
5 shared publications- Chiara Fabbri
Department of Biomedical and Neuromotor Sciences University of Bologna Bologna Italy
4 shared publications Chris Wai Hang Lo
King’s College London
4 shared publications- Evangelos Vassos
Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London
4 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1-9
Understanding antidepressant change patterns in the UK Biobank
Background: Antidepressants are the most frequently prescribed medications in psychiatry. Medical records of thousands of individuals provide a valuable opportunity to explore prescribing patterns and identify factors that influence treatment outcomes. Aims: To investigate antidepressant change patterns in depression and non-depression indications and assess clinical and genetic factors associated with outcomes of antidepressant treatment. Methods: Using primary care records from the UK Biobank, we examined outcomes including number of antidepressant changes and discontinuation due to either side-effects or inadequate response. Genetic analyses including heritability estimation, genetic correlation and polygenic score association were performed. Results: A total of 82 633 individuals were prescribed at least 1 antidepressant. Of these, 28 332 individuals with at least 1 primary care depression diagnosis were classified as the depression group, and 24 543 individuals without evidence of depression were classified as the non-depression group. Citalopram and fluoxetine were the most prescribed antidepressants for depression, whereas amitriptyline dominated prescriptions for non-depression indications. Individuals with depression were more likely to stay on antidepressants longer than those without depression and to follow preferred antidepressants that changed over time. Antidepressant changes and discontinuation were associated with a range of psychiatric and somatic conditions, including recurrent depression (early discontinuation: odds ratio = 1.96; late discontinuation: odds ratio = 2.63) and anxiety (early discontinuation: odds ratio = 1.37; late discontinuation: odds ratio = 1.99) in the depression group, and pain-related conditions in the non-depression group. Genetic analyses identified two novel variants associated with early discontinuation of selective serotonin reuptake inhibitors. Notable genetic overlap was shown between these outcomes and multiple psychiatric and physical traits, including the number of antidepressant changes with anxiety and depression ( r g = 0.81–0.83), and polygenic scores for depression and attention-deficit hyperactivity disorder showed significant predictive value with respect to treatment outcomes. Conclusions: These findings characterise antidepressant change patterns in primary care records and highlight the potential value of integrating clinical and genetic data to better understand factors associated with treatment outcomes.
- 17 July 2026
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- p. 1-9
Open AccessUnderstanding antidepressant change patterns in the UK Biobank
Background: Antidepressants are the most frequently prescribed medications in psychiatry. Medical records of thousands of individuals provide a valuable opportunity to explore prescribing patterns and identify factors that influence treatment outcomes. Aims: To investigate antidepressant change patterns in depression and non-depression indications and assess clinical and genetic factors associated with outcomes of antidepressant treatment. Methods: Using primary care records from the UK Biobank, we examined outcomes including number of antidepressant changes and discontinuation due to either side-effects or inadequate response. Genetic analyses including heritability estimation, genetic correlation and polygenic score association were performed. Results: A total of 82 633 individuals were prescribed at least 1 antidepressant. Of these, 28 332 individuals with at least 1 primary care depression diagnosis were classified as the depression group, and 24 543 individuals without evidence of depression were classified as the non-depression group. Citalopram and fluoxetine were the most prescribed antidepressants for depression, whereas amitriptyline dominated prescriptions for non-depression indications. Individuals with depression were more likely to stay on antidepressants longer than those without depression and to follow preferred antidepressants that changed over time. Antidepressant changes and discontinuation were associated with a range of psychiatric and somatic conditions, including recurrent depression (early discontinuation: odds ratio = 1.96; late discontinuation: odds ratio = 2.63) and anxiety (early discontinuation: odds ratio = 1.37; late discontinuation: odds ratio = 1.99) in the depression group, and pain-related conditions in the non-depression group. Genetic analyses identified two novel variants associated with early discontinuation of selective serotonin reuptake inhibitors. Notable genetic overlap was shown between these outcomes and multiple psychiatric and physical traits, including the number of antidepressant changes with anxiety and depression ( r g = 0.81–0.83), and polygenic scores for depression and attention-deficit hyperactivity disorder showed significant predictive value with respect to treatment outcomes. Conclusions: These findings characterise antidepressant change patterns in primary care records and highlight the potential value of integrating clinical and genetic data to better understand factors associated with treatment outcomes.
- Open Access
Disentangling Perinatal Depression from General Major Depression: A GWAS Meta-Analysis and Genetic Correlation Approach in European Datasets
Perinatal depression (PND), defined as depression occurring during the perinatal period, has a higher heritability than general major depressive disorder (MDD) yet remains understudied. This study aimed to increase power in PND GWAS and explore its genetic architecture. We meta-analysed an existing study by the Psychiatric Genomics Consortium (PGC) with data from the GLAD+ study and UK Biobank (UKB), yielding 25,452 PND cases and 72,131 controls. Linkage disequilibrium score (LDSC) regression was used to compare genetic correlation profiles of PND and general MDD across traits. Gene, gene-set, and tissue expression analyses were also performed. The genetic correlation between PGC PND and UKB-GLAD+ PND was high (0.93). No genome-wide significant loci emerged from the meta-analysis. The SNP-based heritability of PND on the liability scale was 0.089. PND and MDD displayed broadly similar genetic correlation patterns. Still, PND had a significantly higher genetic correlation with anxiety disorders, while MDD showed higher correlations with cannabis use disorder, bipolar disorder, and ADHD. Tissue expression analysis showed the highest enrichment in brain regions like the cortex and nucleus accumbens. The sample size was not large enough to detect genome-wide significant loci, and further analyses in ancestrally diverse datasets are needed. PND definitions were heterogeneous, and precise information on onset timing across studies was lacking. This study, the largest European ancestry meta-analysis of PND to date, suggests distinct genetic factors may differentiate PND from MDD in general. The findings highlight the need for larger and more ancestrally diverse studies to identify genome-wide significant loci.
Open AccessDisentangling Perinatal Depression from General Major Depression: A GWAS Meta-Analysis and Genetic Correlation Approach in European Datasets
Perinatal depression (PND), defined as depression occurring during the perinatal period, has a higher heritability than general major depressive disorder (MDD) yet remains understudied. This study aimed to increase power in PND GWAS and explore its genetic architecture. We meta-analysed an existing study by the Psychiatric Genomics Consortium (PGC) with data from the GLAD+ study and UK Biobank (UKB), yielding 25,452 PND cases and 72,131 controls. Linkage disequilibrium score (LDSC) regression was used to compare genetic correlation profiles of PND and general MDD across traits. Gene, gene-set, and tissue expression analyses were also performed. The genetic correlation between PGC PND and UKB-GLAD+ PND was high (0.93). No genome-wide significant loci emerged from the meta-analysis. The SNP-based heritability of PND on the liability scale was 0.089. PND and MDD displayed broadly similar genetic correlation patterns. Still, PND had a significantly higher genetic correlation with anxiety disorders, while MDD showed higher correlations with cannabis use disorder, bipolar disorder, and ADHD. Tissue expression analysis showed the highest enrichment in brain regions like the cortex and nucleus accumbens. The sample size was not large enough to detect genome-wide significant loci, and further analyses in ancestrally diverse datasets are needed. PND definitions were heterogeneous, and precise information on onset timing across studies was lacking. This study, the largest European ancestry meta-analysis of PND to date, suggests distinct genetic factors may differentiate PND from MDD in general. The findings highlight the need for larger and more ancestrally diverse studies to identify genome-wide significant loci.
- Open Access
Understanding antidepressant change patterns in the UK Biobank
Background: Antidepressants are the most prescribed medications in psychiatry. Medical records provide a valuable opportunity to explore prescribing patterns and to uncover clinical and genetic factors that influence treatment outcomes. Methods: Using longitudinal primary care records from the UK Biobank, we investigated antidepressant change patterns in both depression and non-depression indications. We examined outcomes including the number of antidepressant changes, and discontinuation that is likely due to intolerable side effects or inadequate response. Genetic analyses including heritability estimation, genetic correlation and polygenic score association were performed. Results: A total of 82,633 individuals in the UK Biobank were prescribed at least one of 37 antidepressants. Of these, 28,332 had a depression diagnosis and 24,543 did not. Selective serotonin reuptake inhibitors (SSRIs), including citalopram and fluoxetine, were the most prescribed antidepressants for depression, while tricyclic antidepressants, especially amitriptyline, dominated prescriptions in non-depression indications. Individuals with depression were more likely to stay on antidepressants longer than those without depression, and to follow preferred antidepressant choices that have changed over time. For depression, discontinuation rates for SSRIs were 9% for likely intolerable side effects and 12% for likely nonresponse. Antidepressant change and discontinuation were significantly enriched for psychiatric and somatic conditions, including recurrent depression, anxiety in the depression group, and pain-related conditions in the non-depression group. Genetic analyses identified two novel variants associated with SSRI early discontinuation. Notable genetic overlap was shown between these antidepressant phenotypes and multiple psychiatric and physical traits, and polygenic scores had significant prediction for treatment outcomes. Conclusions: These findings provide a valuable framework for characterising antidepressant change in primary care records and highlight the potential of integrating clinical and genetic data to better understand factors influencing treatment outcomes. Replication in other large-scale medical records will be essential to advance the discovery of genetic variants associated with antidepressant outcomes.
Open AccessUnderstanding antidepressant change patterns in the UK Biobank
Background: Antidepressants are the most prescribed medications in psychiatry. Medical records provide a valuable opportunity to explore prescribing patterns and to uncover clinical and genetic factors that influence treatment outcomes. Methods: Using longitudinal primary care records from the UK Biobank, we investigated antidepressant change patterns in both depression and non-depression indications. We examined outcomes including the number of antidepressant changes, and discontinuation that is likely due to intolerable side effects or inadequate response. Genetic analyses including heritability estimation, genetic correlation and polygenic score association were performed. Results: A total of 82,633 individuals in the UK Biobank were prescribed at least one of 37 antidepressants. Of these, 28,332 had a depression diagnosis and 24,543 did not. Selective serotonin reuptake inhibitors (SSRIs), including citalopram and fluoxetine, were the most prescribed antidepressants for depression, while tricyclic antidepressants, especially amitriptyline, dominated prescriptions in non-depression indications. Individuals with depression were more likely to stay on antidepressants longer than those without depression, and to follow preferred antidepressant choices that have changed over time. For depression, discontinuation rates for SSRIs were 9% for likely intolerable side effects and 12% for likely nonresponse. Antidepressant change and discontinuation were significantly enriched for psychiatric and somatic conditions, including recurrent depression, anxiety in the depression group, and pain-related conditions in the non-depression group. Genetic analyses identified two novel variants associated with SSRI early discontinuation. Notable genetic overlap was shown between these antidepressant phenotypes and multiple psychiatric and physical traits, and polygenic scores had significant prediction for treatment outcomes. Conclusions: These findings provide a valuable framework for characterising antidepressant change in primary care records and highlight the potential of integrating clinical and genetic data to better understand factors influencing treatment outcomes. Replication in other large-scale medical records will be essential to advance the discovery of genetic variants associated with antidepressant outcomes.
- Open Access
Genome-wide analyses of quantitative generalised anxiety symptom severity
We performed a genome-wide association meta-analysis of generalised anxiety symptom severity in 696,563 individuals of European ancestry from 14 cohorts. We identified 82 independent genome-wide significant variants within 76 loci, 41 of which were novel for anxiety. SNP-based heritability was 5.9% (SE = 0.19%). Polygenic scores were significantly associated with anxiety symptom severity and disorder in European, African, and South Asian ancestry samples (r2=1.2%-3.4%). Significant genetic correlations were estimated with numerous mental and physical health traits, including case-control anxiety, neuroticism and depression (rg=0.71-0.86), irritable bowel syndrome (rg=0.57), coronary artery disease, endometriosis, and migraine (rg=0.20-0.27). Gene-based and pathway analyses implicated synaptic and axonal processes, with enriched expression in the brain. These findings highlight the additional value of a dimensional approach in anxiety genetics.
Open AccessGenome-wide analyses of quantitative generalised anxiety symptom severity
We performed a genome-wide association meta-analysis of generalised anxiety symptom severity in 696,563 individuals of European ancestry from 14 cohorts. We identified 82 independent genome-wide significant variants within 76 loci, 41 of which were novel for anxiety. SNP-based heritability was 5.9% (SE = 0.19%). Polygenic scores were significantly associated with anxiety symptom severity and disorder in European, African, and South Asian ancestry samples (r2=1.2%-3.4%). Significant genetic correlations were estimated with numerous mental and physical health traits, including case-control anxiety, neuroticism and depression (rg=0.71-0.86), irritable bowel syndrome (rg=0.57), coronary artery disease, endometriosis, and migraine (rg=0.20-0.27). Gene-based and pathway analyses implicated synaptic and axonal processes, with enriched expression in the brain. These findings highlight the additional value of a dimensional approach in anxiety genetics.
- Open Access
- 28 May 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0324189
The UK Biobank mental health enhancement 2022: Methods and results
Background: This paper introduces the UK Biobank (UKB) second mental health questionnaire (MHQ2), describes its design, the respondents and some notable findings. UKB is a large cohort study with over 500,000 volunteer participants aged 40–69 years when recruited in 2006–2010. It is an important resource of extensive health, genetic and biomarker data. Enhancements to UKB enrich the data available. MHQ2 is an enhancement designed to enable and facilitate research with psychosocial and mental health aspects. Methods: UKB sent participants a link to MHQ2 by email in October-November 2022. The MHQ2 was designed by a multi-institutional consortium to build on MHQ1. It characterises lifetime depression further, adds data on panic disorder and eating disorders, repeats ‘current’ mental health measures and updates information about social circumstances. It includes established measures, such as the PHQ-9 for current depression and CIDI-SF for lifetime panic, as well as bespoke questions. Algorithms and R code were developed to facilitate analysis. Results: At the time of analysis, MHQ2 results were available for 169,253 UKB participants, of whom 111,275 had also completed the earlier MHQ1. Characteristics of respondents and the whole UKB cohort are compared. The major phenotypes are lifetime: depression (18%); panic disorder (4.0%); a specific eating disorder (2.8%); and bipolar affective disorder I (0.4%). All mental disorders are found less with older age and also seem to be related to selected social factors. In those participants who answered both MHQ1 (2016) and MHQ2 (2022), current mental health measure showed that fewer respondents have harmful alcohol use than in 2016 (relative risk 0.84), but current depression (RR 1.07) and anxiety (RR 0.98) have not fallen, as might have been expected given the relationship with age. We also compare lifetime concepts for test-retest reliability. Conclusions: There are some drawbacks to UKB due to its lack of population representativeness, but where the research question does not depend on this, it offers exceptional resources that any researcher can apply to access. This paper has just scratched the surface of the results from MHQ2 and how this can be combined with other tranches of UKB data, but we predict it will enable many future discoveries about mental health and health in general.
- 28 May 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0324189
Open AccessThe UK Biobank mental health enhancement 2022: Methods and results
Background: This paper introduces the UK Biobank (UKB) second mental health questionnaire (MHQ2), describes its design, the respondents and some notable findings. UKB is a large cohort study with over 500,000 volunteer participants aged 40–69 years when recruited in 2006–2010. It is an important resource of extensive health, genetic and biomarker data. Enhancements to UKB enrich the data available. MHQ2 is an enhancement designed to enable and facilitate research with psychosocial and mental health aspects. Methods: UKB sent participants a link to MHQ2 by email in October-November 2022. The MHQ2 was designed by a multi-institutional consortium to build on MHQ1. It characterises lifetime depression further, adds data on panic disorder and eating disorders, repeats ‘current’ mental health measures and updates information about social circumstances. It includes established measures, such as the PHQ-9 for current depression and CIDI-SF for lifetime panic, as well as bespoke questions. Algorithms and R code were developed to facilitate analysis. Results: At the time of analysis, MHQ2 results were available for 169,253 UKB participants, of whom 111,275 had also completed the earlier MHQ1. Characteristics of respondents and the whole UKB cohort are compared. The major phenotypes are lifetime: depression (18%); panic disorder (4.0%); a specific eating disorder (2.8%); and bipolar affective disorder I (0.4%). All mental disorders are found less with older age and also seem to be related to selected social factors. In those participants who answered both MHQ1 (2016) and MHQ2 (2022), current mental health measure showed that fewer respondents have harmful alcohol use than in 2016 (relative risk 0.84), but current depression (RR 1.07) and anxiety (RR 0.98) have not fallen, as might have been expected given the relationship with age. We also compare lifetime concepts for test-retest reliability. Conclusions: There are some drawbacks to UKB due to its lack of population representativeness, but where the research question does not depend on this, it offers exceptional resources that any researcher can apply to access. This paper has just scratched the surface of the results from MHQ2 and how this can be combined with other tranches of UKB data, but we predict it will enable many future discoveries about mental health and health in general.
- Open Access
The UK Biobank Mental Health Enhancement 2022: Methods and Results
Background: This paper introduces the UK Biobank (UKB) second mental health questionnaire (MHQ2), describes its design, the respondents and some notable findings. UKB is a large cohort study with over 500,000 volunteer participants aged 40-69 years when recruited in 2006-2010. It is an important resource of extensive health, genetic and biomarker data. Enhancements to UKB enrich the data available. MHQ2 is an enhancement designed to enable and facilitate research with psychosocial and mental health aspects. Methods: UKB sent participants a link to MHQ2 by email in October-November 2022. The MHQ2 was designed by a multi-institutional consortium to build on MHQ1. It characterises lifetime depression further, adds data on panic disorder and eating disorders, repeats ‘current’ mental health measures and updates information about social circumstances. It includes established measures, such as the PHQ-9 for current depression and CIDI-SF for lifetime panic, as well as bespoke questions. Algorithms and R code were developed to facilitate analysis. Results: At the time of analysis, MHQ2 results were available for 169,253 UKB participants, of whom 111,275 had also completed the earlier MHQ1. Characteristics of respondents and the whole UKB cohort are compared. The major phenotypes are lifetime: depression (18%); panic disorder (4.0%); a specific eating disorder (2.8%); and bipolar affective disorder I (0.4%). All mental disorders are found less with older age and also seem to be related to selected social factors. In those participants who answered both MHQ1 (2016) and MHQ2 (2022), current mental health measure showed that fewer respondents have harmful alcohol use than in 2016 (relative risk 0.84), but current depression (RR 1.07) and anxiety (RR 0.98) have not fallen, as might have been expected given the relationship with age. We also compare lifetime concepts for test-retest reliability. Conclusions: There are some drawbacks to UKB due to its lack of population representativeness, but where the research question does not depend on this, it offers exceptional resources that any researcher can apply to access. This paper has just scratched the surface of the results from MHQ2 and how this can be combined with other tranches of UKB data, but we predict it will enable many future discoveries about mental health and health in general.
Open AccessThe UK Biobank Mental Health Enhancement 2022: Methods and Results
Background: This paper introduces the UK Biobank (UKB) second mental health questionnaire (MHQ2), describes its design, the respondents and some notable findings. UKB is a large cohort study with over 500,000 volunteer participants aged 40-69 years when recruited in 2006-2010. It is an important resource of extensive health, genetic and biomarker data. Enhancements to UKB enrich the data available. MHQ2 is an enhancement designed to enable and facilitate research with psychosocial and mental health aspects. Methods: UKB sent participants a link to MHQ2 by email in October-November 2022. The MHQ2 was designed by a multi-institutional consortium to build on MHQ1. It characterises lifetime depression further, adds data on panic disorder and eating disorders, repeats ‘current’ mental health measures and updates information about social circumstances. It includes established measures, such as the PHQ-9 for current depression and CIDI-SF for lifetime panic, as well as bespoke questions. Algorithms and R code were developed to facilitate analysis. Results: At the time of analysis, MHQ2 results were available for 169,253 UKB participants, of whom 111,275 had also completed the earlier MHQ1. Characteristics of respondents and the whole UKB cohort are compared. The major phenotypes are lifetime: depression (18%); panic disorder (4.0%); a specific eating disorder (2.8%); and bipolar affective disorder I (0.4%). All mental disorders are found less with older age and also seem to be related to selected social factors. In those participants who answered both MHQ1 (2016) and MHQ2 (2022), current mental health measure showed that fewer respondents have harmful alcohol use than in 2016 (relative risk 0.84), but current depression (RR 1.07) and anxiety (RR 0.98) have not fallen, as might have been expected given the relationship with age. We also compare lifetime concepts for test-retest reliability. Conclusions: There are some drawbacks to UKB due to its lack of population representativeness, but where the research question does not depend on this, it offers exceptional resources that any researcher can apply to access. This paper has just scratched the surface of the results from MHQ2 and how this can be combined with other tranches of UKB data, but we predict it will enable many future discoveries about mental health and health in general.
- Open Access
Antidepressant switching as a proxy phenotype for drug non-response: investigating clinical, demographic and genetic characteristics
Background: Selective serotonin reuptake inhibitors (SSRIs) are a first-line pharmacological therapy in major depressive disorder (MDD), but treatment response rates are low. Clinical trials lack the power to study the genetic contribution to SSRI response. Real-world evidence from electronic health records provides larger sample sizes, but novel response definitions are needed to accurately define SSRI non-responders. Methods: In UK Biobank (UKB) and Generation Scotland, SSRI switching was defined using a ≤ 90-day gap between prescriptions for an SSRI and another antidepressant in primary care. Non-switchers were participants with ≥ 3 consecutive prescriptions for an SSRI. In UKB, clinical, demographic and polygenic score (PGS) associations with switching were determined, and the common-variant heritability was estimated. Results: In UKB, 5,133 (13.2%) SSRI switchers and 33,680 non-switchers were defined. The mean time to switch was 28 days (IQR: 17-49). Switching patterns were consistent across UKB and Generation Scotland (n = 498 switchers). Higher annual income and educational levels (OR [95% CI] for university degree: 0.73 [0.67-0.79], compared to no qualifications) were associated with lower levels of switching. PGS for non-remission, based on clinical studies, were associated with increased risk of switching (OR: 1.07 [1.02-1.12], p=0.007). MDD PGS and family history of depression were not significantly associated with switching. Using GCTB, the heritability of SSRI switching was approximately 4% (SE: 0.016) on the observed scale. Conclusion: This study identified SSRI switching as a proxy of non-response, scalable across biobanks with EHR, capturing demographic and genetics of treatment non-response, and independent of MDD genetics.
Open AccessAntidepressant switching as a proxy phenotype for drug non-response: investigating clinical, demographic and genetic characteristics
Background: Selective serotonin reuptake inhibitors (SSRIs) are a first-line pharmacological therapy in major depressive disorder (MDD), but treatment response rates are low. Clinical trials lack the power to study the genetic contribution to SSRI response. Real-world evidence from electronic health records provides larger sample sizes, but novel response definitions are needed to accurately define SSRI non-responders. Methods: In UK Biobank (UKB) and Generation Scotland, SSRI switching was defined using a ≤ 90-day gap between prescriptions for an SSRI and another antidepressant in primary care. Non-switchers were participants with ≥ 3 consecutive prescriptions for an SSRI. In UKB, clinical, demographic and polygenic score (PGS) associations with switching were determined, and the common-variant heritability was estimated. Results: In UKB, 5,133 (13.2%) SSRI switchers and 33,680 non-switchers were defined. The mean time to switch was 28 days (IQR: 17-49). Switching patterns were consistent across UKB and Generation Scotland (n = 498 switchers). Higher annual income and educational levels (OR [95% CI] for university degree: 0.73 [0.67-0.79], compared to no qualifications) were associated with lower levels of switching. PGS for non-remission, based on clinical studies, were associated with increased risk of switching (OR: 1.07 [1.02-1.12], p=0.007). MDD PGS and family history of depression were not significantly associated with switching. Using GCTB, the heritability of SSRI switching was approximately 4% (SE: 0.016) on the observed scale. Conclusion: This study identified SSRI switching as a proxy of non-response, scalable across biobanks with EHR, capturing demographic and genetics of treatment non-response, and independent of MDD genetics.
- Open Access
- 31 August 2024
- Published by Springer Nature in Translational Psychiatry
- Vol. 14 (1) , 1
Correction: Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis
- 31 August 2024
- Published by Springer Nature in Translational Psychiatry
- Vol. 14 (1) , 1
Open AccessCorrection: Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis
- Open Access
- 19 July 2024
- Published by Springer Nature in Translational Psychiatry
- Vol. 14 (1) , 1-8
Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis
Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual clinical and genetic data from 13 studies of European and East Asian ancestry populations were collected. The antidepressant response was clinically assessed as remission and percentage improvement. Imputed genotype was used to translate genetic polymorphisms to metabolic phenotypes (poor, intermediate, normal, and rapid+ultrarapid) of CYP2C19 and CYP2D6. CYP2D6 structural variants cannot be imputed from genotype data, limiting the determination of metabolic phenotypes, and precluding testing for association with response. The association of CYP2C19 metabolic phenotypes with treatment response was examined using normal metabolizers as the reference. Among 5843 depression patients, a higher remission rate was found in CYP2C19 poor metabolizers compared to normal metabolizers at nominal significance but did not survive after multiple testing correction (OR = 1.46, 95% CI [1.03, 2.06], p = 0.033, heterogeneity I2 = 0%, subgroup difference p = 0.72). No metabolic phenotype was associated with percentage improvement from baseline. After stratifying by antidepressants primarily metabolized by CYP2C19, no association was found between metabolic phenotypes and antidepressant response. Metabolic phenotypes showed differences in frequency, but not effect, between European- and East Asian-ancestry studies. In conclusion, metabolic phenotypes imputed from genetic variants using genotype were not associated with antidepressant response. CYP2C19 poor metabolizers could potentially contribute to antidepressant efficacy with more evidence needed. Sequencing and targeted pharmacogenetic testing, alongside information on side effects, antidepressant dosage, depression measures, and diverse ancestry studies, would more fully capture the influence of metabolic phenotypes.
- 19 July 2024
- Published by Springer Nature in Translational Psychiatry
- Vol. 14 (1) , 1-8
Open AccessMetabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis
Cytochrome P450 enzymes including CYP2C19 and CYP2D6 are important for antidepressant metabolism and polymorphisms of these genes have been determined to predict metabolite levels. Nonetheless, more evidence is needed to understand the impact of genetic variations on antidepressant response. In this study, individual clinical and genetic data from 13 studies of European and East Asian ancestry populations were collected. The antidepressant response was clinically assessed as remission and percentage improvement. Imputed genotype was used to translate genetic polymorphisms to metabolic phenotypes (poor, intermediate, normal, and rapid+ultrarapid) of CYP2C19 and CYP2D6. CYP2D6 structural variants cannot be imputed from genotype data, limiting the determination of metabolic phenotypes, and precluding testing for association with response. The association of CYP2C19 metabolic phenotypes with treatment response was examined using normal metabolizers as the reference. Among 5843 depression patients, a higher remission rate was found in CYP2C19 poor metabolizers compared to normal metabolizers at nominal significance but did not survive after multiple testing correction (OR = 1.46, 95% CI [1.03, 2.06], p = 0.033, heterogeneity I2 = 0%, subgroup difference p = 0.72). No metabolic phenotype was associated with percentage improvement from baseline. After stratifying by antidepressants primarily metabolized by CYP2C19, no association was found between metabolic phenotypes and antidepressant response. Metabolic phenotypes showed differences in frequency, but not effect, between European- and East Asian-ancestry studies. In conclusion, metabolic phenotypes imputed from genetic variants using genotype were not associated with antidepressant response. CYP2C19 poor metabolizers could potentially contribute to antidepressant efficacy with more evidence needed. Sequencing and targeted pharmacogenetic testing, alongside information on side effects, antidepressant dosage, depression measures, and diverse ancestry studies, would more fully capture the influence of metabolic phenotypes.
- Open Access
Prediction of antidepressant side effects in the Genetic Link to Anxiety and Depression Study
Antidepressants are the most common treatment for moderate or severe depression. Side effects are crucial indicators for antidepressants, but their occurrence varies widely among individuals. In this study, we leveraged genetic and medical data from self-reported questionnaires in the Genetic Links to Anxiety and Depression (GLAD) study to build prediction models of side effects and subsequent discontinuation across three antidepressant classes (SSRI, SNRI, tricyclic antidepressant (TCA)) at the first and the last (most recent) year of prescription. We included 259 predictors spanning genetic, clinical, illness, demographic, and antidepressant information. Six prediction models were trained, and their performance was compared. The final dataset comprised 4,354 individuals taking SSRI in the first prescription and 3,414 taking SSRI, SNRI or TCA in the last year of prescription. In the first year, the best area under the receiver operating characteristic curve (AUROC) for predicting SSRI discontinuation and side effects were 0.65 and 0.60. In the last year of SSRI prescription, the highest AUROC reached 0.73 for discontinuation and 0.87 for side effects. Models for predicting discontinuation and side effects of SNRI and TCA showed comparable performance. The history of side effects and discontinuation of antidepressant use were the most influential predictors of the outcomes in the last year of prescription. When examining 30 common antidepressant side effect symptoms, most of them were differentially prevalent between antidepressant classes. Our findings suggested the feasibility of predicting antidepressant side effects using a self-reported questionnaire, particularly for the last prescription. These results could contribute valuable insights for the development of clinical decisions aimed at optimising treatment selection with enhanced tolerability but require replication in medical record linkage or prospective data.
Open AccessPrediction of antidepressant side effects in the Genetic Link to Anxiety and Depression Study
Antidepressants are the most common treatment for moderate or severe depression. Side effects are crucial indicators for antidepressants, but their occurrence varies widely among individuals. In this study, we leveraged genetic and medical data from self-reported questionnaires in the Genetic Links to Anxiety and Depression (GLAD) study to build prediction models of side effects and subsequent discontinuation across three antidepressant classes (SSRI, SNRI, tricyclic antidepressant (TCA)) at the first and the last (most recent) year of prescription. We included 259 predictors spanning genetic, clinical, illness, demographic, and antidepressant information. Six prediction models were trained, and their performance was compared. The final dataset comprised 4,354 individuals taking SSRI in the first prescription and 3,414 taking SSRI, SNRI or TCA in the last year of prescription. In the first year, the best area under the receiver operating characteristic curve (AUROC) for predicting SSRI discontinuation and side effects were 0.65 and 0.60. In the last year of SSRI prescription, the highest AUROC reached 0.73 for discontinuation and 0.87 for side effects. Models for predicting discontinuation and side effects of SNRI and TCA showed comparable performance. The history of side effects and discontinuation of antidepressant use were the most influential predictors of the outcomes in the last year of prescription. When examining 30 common antidepressant side effect symptoms, most of them were differentially prevalent between antidepressant classes. Our findings suggested the feasibility of predicting antidepressant side effects using a self-reported questionnaire, particularly for the last prescription. These results could contribute valuable insights for the development of clinical decisions aimed at optimising treatment selection with enhanced tolerability but require replication in medical record linkage or prospective data.